Ainos Receives Taiwan Hospital's Approval for Veldona Trial in Sjogren's Syndrome

MT Newswires Live11-11

Ainos (AIMD) said Monday it has received approval from the Institutional Review Board of Shuang Ho Hospital in Taiwan for the conduct of a clinical study of Veldona to treat Sjogren's syndrome.

The company said it intends to submit to Taiwan's Food and Drug Administration by the end of this year and expects to receive all regulatory approvals in Q1 next year as well as conduct a site initiation visit around April.

The study aims to evaluate Veldona's efficacy in improving salivary flow and reducing dryness symptoms in patients with Sjogren's syndrome, Ainos said, adding it expects to enroll 24 participants for a 24- to 48-week treatment period.

Shares of the company were down 2.2% in recent Monday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2482787854?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-11 22:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2482787854","market":"us","top_or_hot":-1,"title":"Ainos Receives Taiwan Hospital's Approval for Veldona Trial in Sjogren's Syndrome","media":"MT Newswires Live","content":"<html><body><p> Ainos (AIMD) said Monday it has received approval from the Institutional Review Board of Shuang Ho Hospital in Taiwan for the conduct of a clinical study of Veldona to treat Sjogren's syndrome.</p><p>The company said it intends to submit to Taiwan's Food and Drug Administration by the end of this year and expects to receive all regulatory approvals in Q1 next year as well as conduct a site initiation visit around April.</p><p>The study aims to evaluate Veldona's efficacy in improving salivary flow and reducing dryness symptoms in patients with Sjogren's syndrome, Ainos said, adding it expects to enroll 24 participants for a 24- to 48-week treatment period.</p><p>Shares of the company were down 2.2% in recent Monday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ainos Receives Taiwan Hospital's Approval for Veldona Trial in Sjogren's Syndrome</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAinos Receives Taiwan Hospital's Approval for Veldona Trial in Sjogren's Syndrome\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-11 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ainos (AIMD) said Monday it has received approval from the Institutional Review Board of Shuang Ho Hospital in Taiwan for the conduct of a clinical study of Veldona to treat Sjogren's syndrome.The ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AIMD","symbol_name":"AINOS Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2482787854","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482787854","pubTimestamp":1731334416,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Ainos  said Monday it has received approval from the Institutional Review Board of Shuang Ho Hospital in Taiwan for the conduct of a clinical study of Veldona to treat Sjogren's syndrome.The company said it intends to submit to Taiwan's Food and Drug Administration by the end of this year and expects to receive all regulatory approvals in Q1 next year as well as conduct a site initiation visit around April.The study aims to evaluate Veldona's efficacy in improving salivary flow and reducing dryness symptoms in patients with Sjogren's syndrome, Ainos said, adding it expects to enroll 24 participants for a 24- to 48-week treatment period.Shares of the company were down 2.2% in recent Monday premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AIMD":"AINOS Inc.","BK4139":"生物科技"},"translate_title":"艾诺斯获得台湾医院批准Veldona治疗干燥综合征试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AIMD":0.9},"content_text":"Ainos (AIMD) said Monday it has received approval from the Institutional Review Board of Shuang Ho Hospital in Taiwan for the conduct of a clinical study of Veldona to treat Sjogren's syndrome.The company said it intends to submit to Taiwan's Food and Drug Administration by the end of this year and expects to receive all regulatory approvals in Q1 next year as well as conduct a site initiation visit around April.The study aims to evaluate Veldona's efficacy in improving salivary flow and reducing dryness symptoms in patients with Sjogren's syndrome, Ainos said, adding it expects to enroll 24 participants for a 24- to 48-week treatment period.Shares of the company were down 2.2% in recent Monday premarket activity.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482787854"}